An interview with Dr Beverley Isherwood.
Biogen cuts almost one-third of Reata’s staff following $7B buyout
Biogen made a big M&A splash in July with its $7.3 billion buyout of Reata Pharmaceuticals, which had just secured FDA approval for a rare